Abstract
Stereotactic body radiotherapy (SBRT) has firmly established its role in the management of stage I non-small cell lung cancer (NSCLC). Results from trials are difficult to generalize to the entire patient population in the real world. In addition, in contrast to trials, real-world data provides increased statistical power to study rare outcomes and their predictors. The primary aim of this nationwide study was to determine the real-world incidence of acute toxicity and 90-day mortality in patients treated with SBRT for stage I NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
